Skip to content
AetionApr 2, 2025< 1 min read

Increasing the Utility of Real-World Data to Inform Public Health Decision Making Through a US-based Private–Public Partnership

The urgency of the COVID-19 pandemic highlighted the need for rapid, reliable real-world evidence (RWE) to guide public health and regulatory decisions. In response, a collaborative public-private partnership, including the FDA and Aetion, launched an initiative to leverage real-world data (RWD) for near real-time insights into the virus, its treatments, and its evolving clinical landscape.

Study Overview

This publication outlines the multi-phase approach taken to accelerate RWE generation during the COVID-19 pandemic. It includes strategies for selecting and analyzing fit-for-purpose RWD in a rapidly changing environment and the trial emulation methods used to ensure observational study validity amid evolving treatment protocols. 

Through this research, we learn how cross-sector collaboration and real-time evidence generation informed public health decisions, paving the way for researchers to develop new tools and best practices to inform future public health responses. 

Read the full article here.

RELATED ARTICLES